TY - JOUR
T1 - Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
AU - Rekers, Nicolle H.
AU - Zegers, Catharina M. L.
AU - Yaromina, Ala
AU - Lieuwes, Natasja G.
AU - Biemans, Rianne
AU - Senden-Gijsbers, Birgit L. M. G.
AU - Losen, Mario
AU - Van Limbergen, Evert J.
AU - Germeraad, Wilfred T. V.
AU - Neri, Dario
AU - Dubois, Ludwig
AU - Lambin, Philippe
PY - 2015/9
Y1 - 2015/9
N2 - Background and purpose: Recently, we have shown that radiotherapy (RT) combined with the immunocytokine L19-1L2 can induce long-lasting antitumour effects, dependent on ED-B expression and infiltration of cytotoxic T cells. On the other hand, in certain tumours, IL2 treatment can trigger a natural killer cell (NK) immune response. The aim of this study is to investigate the therapeutic effect of our combination therapy in the ED-B positive F9 teratocarcinoma model, lacking MHCI expression and known to be dependent on NK immune responses. Material and methods: In syngeneic F9 tumour bearing 129/FvHsd mice tumour growth delay was evaluated after local tumour irradiation (10 Gy) combined with systemic administration of L19-1L2. Immunological responses were investigated using flow cytometry. Results: Tumour growth delay of L19-1L2 can be further improved by a single dose of RT administered before immunotherapy, but not during immunotherapy. Furthermore, treatment of L19-1L2 favours a NK response and lacks cytotoxic T cell tumour infiltrating immune cells, which may be explained by the absence of MHCI expression. Conclusion: An additive effect can be detected when the NK dependent F9 tumour model is treated with radiotherapy and L19-11.2 and therefore this combination could be useful in the absence of tumoural MHCI expression.
AB - Background and purpose: Recently, we have shown that radiotherapy (RT) combined with the immunocytokine L19-1L2 can induce long-lasting antitumour effects, dependent on ED-B expression and infiltration of cytotoxic T cells. On the other hand, in certain tumours, IL2 treatment can trigger a natural killer cell (NK) immune response. The aim of this study is to investigate the therapeutic effect of our combination therapy in the ED-B positive F9 teratocarcinoma model, lacking MHCI expression and known to be dependent on NK immune responses. Material and methods: In syngeneic F9 tumour bearing 129/FvHsd mice tumour growth delay was evaluated after local tumour irradiation (10 Gy) combined with systemic administration of L19-1L2. Immunological responses were investigated using flow cytometry. Results: Tumour growth delay of L19-1L2 can be further improved by a single dose of RT administered before immunotherapy, but not during immunotherapy. Furthermore, treatment of L19-1L2 favours a NK response and lacks cytotoxic T cell tumour infiltrating immune cells, which may be explained by the absence of MHCI expression. Conclusion: An additive effect can be detected when the NK dependent F9 tumour model is treated with radiotherapy and L19-11.2 and therefore this combination could be useful in the absence of tumoural MHCI expression.
KW - Cancer
KW - ED-B
KW - Immunotherapy
KW - F9
KW - MHCI
U2 - 10.1016/j.radonc.2015.06.019
DO - 10.1016/j.radonc.2015.06.019
M3 - Article
C2 - 26138057
SN - 0167-8140
VL - 116
SP - 438
EP - 442
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -